LEO LABORATORIES LIMITED

🇮🇪Ireland
Ownership
-
Employees
-
Market Cap
-
Website

Tacrolimus Blood Levels After Topical Application of Tacrolimus on Healthy Skin

Phase 1
Completed
Conditions
Interventions
First Posted Date
2018-09-17
Last Posted Date
2022-04-21
Lead Sponsor
LEO Pharma
Target Recruit Count
24
Registration Number
NCT03673527
Locations
🇩🇪

Investigational site, Neu-Ulm, Bavaria, Germany

Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis

First Posted Date
2018-09-13
Last Posted Date
2024-10-26
Lead Sponsor
LEO Pharma
Target Recruit Count
13
Registration Number
NCT03669757
Locations
🇩🇪

Investigational Site, Hamburg, Germany

Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND

Phase 3
Completed
Conditions
Interventions
First Posted Date
2018-07-16
Last Posted Date
2024-08-05
Lead Sponsor
LEO Pharma
Target Recruit Count
1672
Registration Number
NCT03587805
Locations
🇯🇵

LEO Pharma Investigational Site 1, Osaka, Japan

🇯🇵

LEO Pharma Investigational Site 2, Osaka, Japan

🇬🇧

LEO Pharma Investigational Site, Walsall, United Kingdom

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

First Posted Date
2018-06-19
Last Posted Date
2024-07-31
Lead Sponsor
LEO Pharma
Target Recruit Count
215
Registration Number
NCT03562377
Locations
🇨🇦

LEO Pharma Investigational Site, Verdun, Quebec, Canada

🇺🇸

Leo Pharma Investigational Site, Spokane, Washington, United States

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

First Posted Date
2018-06-14
Last Posted Date
2024-10-26
Lead Sponsor
LEO Pharma
Target Recruit Count
40
Registration Number
NCT03556592
Locations
🇳🇱

LEO Pharma Investigational Site, Leiden, Netherlands

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

Phase 3
Completed
Conditions
Interventions
First Posted Date
2018-05-16
Last Posted Date
2024-08-29
Lead Sponsor
LEO Pharma
Target Recruit Count
301
Registration Number
NCT03526861
Locations
🇬🇧

Leo Pharma Investigationel Site, London, United Kingdom

🇧🇪

Leo Pharma Investigational Site, Maldegem, Belgium

🇨🇦

LEO Pharma Investigational Site, Saskatoon, Saskatchewan, Canada

Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis

Phase 1
Completed
Conditions
Interventions
First Posted Date
2018-05-02
Last Posted Date
2024-10-26
Lead Sponsor
LEO Pharma
Target Recruit Count
47
Registration Number
NCT03514511
Locations
🇬🇧

Investigational site, Liverpool, United Kingdom

🇬🇧

LEO Pharma investigational site, Manchester, United Kingdom

Dermatopharmacokinetic Trial of LEO 90100 Foam

Phase 1
Completed
Conditions
Interventions
First Posted Date
2018-03-26
Last Posted Date
2018-08-16
Lead Sponsor
LEO Pharma
Target Recruit Count
58
Registration Number
NCT03476746
Locations
🇯🇵

Investigational site, Fukuoka, Japan

Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects

First Posted Date
2018-02-22
Last Posted Date
2019-12-10
Lead Sponsor
LEO Pharma
Target Recruit Count
20
Registration Number
NCT03442244
Locations
🇯🇵

Medical Co. LTA HAKATA clinic, Fukuoka, Japan

Body PSOriasis: Long-term Relapse CONTROL

Completed
Conditions
First Posted Date
2018-01-18
Last Posted Date
2021-03-16
Lead Sponsor
LEO Pharma
Target Recruit Count
764
Registration Number
NCT03402828
Locations
🇷🇺

The State Autonomous Foundation of Public Health "Republic Clinical Dermatovenereological Dispensary" of the Republic of Tatarstan, Kazan, Tatarstan, Russian Federation

© Copyright 2024. All Rights Reserved by MedPath